NASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis $204.92 +8.88 (+4.53%) Closing price 04:00 PM EasternExtended Trading$204.78 -0.13 (-0.07%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Natera Stock (NASDAQ:NTRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Natera alerts:Sign Up Key Stats Today's Range$197.16▼$205.3650-Day Range$182.65▼$219.8252-Week Range$131.81▼$256.36Volume1.51 million shsAverage Volume1.32 million shsMarket Capitalization$29.35 billionP/E RatioN/ADividend YieldN/APrice Target$256.60Consensus RatingModerate Buy Company Overview Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients. Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection. The company also provides genetic counseling and supports clinical use through validation studies and peer-reviewed publications. Natera operates certified clinical laboratories and serves healthcare providers, hospitals, fertility clinics, and biopharmaceutical partners in the United States and in international markets. The company engages in collaborations with clinicians and drug developers to support clinical trials, companion diagnostic development, and translational research. Its offerings are positioned to support both clinical decision-making and research applications across multiple therapeutic areas. Founded in the mid-2000s and headquartered in the San Francisco Bay Area, Natera is a publicly traded company listed on the Nasdaq. The business emphasizes ongoing research and product development, regulatory compliance, and scientific validation to expand the clinical utility of its genetic testing platforms. Its leadership and scientific teams comprise professionals with experience in genomics, diagnostics, and laboratory medicine. AI Generated. May Contain Errors. Read More Natera Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreNTRA MarketRank™: Natera scored higher than 79% of companies evaluated by MarketBeat, and ranked 142nd out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNatera has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 1 strong buy rating, 14 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialNatera has a consensus price target of $256.60, representing about 25.2% upside from its current price of $204.92.Amount of Analyst CoverageNatera has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Natera's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($1.49) to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -125.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -125.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 16.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Natera's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.00% of the float of Natera has been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 3.31, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Natera has recently increased by 6.70%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.15 News SentimentNatera has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Natera this week, compared to 10 articles on an average week.Search Interest13 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.MarketBeat Follows10 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,747,808.00 in company stock.Percentage Held by Insiders5.63% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Natera's insider trading history. Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NTRA Stock News HeadlinesEXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients EnrolledMay 20 at 8:41 AM | finance.yahoo.comIs It Time To Reassess Natera (NTRA) After The Recent Share Price PullbackMay 19 at 10:10 PM | uk.finance.yahoo.comTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that night, the dollar has lost over 85% of its purchasing power - and retirement savers have absorbed the cost. U.S. Code Title 31, Section 5117 gives the Treasury authority to reprice America's gold reserves from $42 per ounce to today's market value - a gap of 107x. More than 60 million Americans can move into physical gold inside a retirement account, tax-free and penalty-free.May 20 at 1:00 AM | Americas Gold Company (Ad)Natera jumps after Signatera CDx wins FDA companion diagnostic approval in bladder cancerMay 18 at 1:50 PM | quiverquant.comQSignateraâ„¢ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)May 15, 2026 | businesswire.comNatera, Inc. (NASDAQ:NTRA) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 13, 2026 | americanbankingnews.comInsider Selling: Natera (NASDAQ:NTRA) Insider Sells 291 Shares of StockMay 6, 2026 | insidertrades.comInsider Selling: Natera (NASDAQ:NTRA) Insider Sells 1,688 Shares of StockApril 30, 2026 | insidertrades.comSee More Headlines NTRA Stock Analysis - Frequently Asked Questions How have NTRA shares performed this year? Natera's stock was trading at $229.09 at the beginning of 2026. Since then, NTRA shares have decreased by 10.6% and is now trading at $204.92. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) announced its quarterly earnings results on Thursday, February, 26th. The medical research company reported $0.35 EPS for the quarter, topping the consensus estimate of ($0.46) by $0.81. The medical research company had revenue of $665.50 million for the quarter, compared to analysts' expectations of $600.68 million. Natera had a negative net margin of 9.05% and a negative trailing twelve-month return on equity of 14.74%. Read the conference call transcript. When did Natera IPO? Natera (NTRA) raised $175 million in an IPO on Thursday, July 2nd 2015. The company issued 10,000,000 shares at $17.00-$18.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Top institutional investors of Natera include Arrowstreet Capital Limited Partnership (0.83%), Maverick Capital Ltd. (0.82%), Bank of America Corp DE (0.51%) and Sumitomo Mitsui Trust Group Inc. (0.49%). Insiders that own company stock include Roelof Botha, Matthew Rabinowitz, Daniel Rabinowitz, John Fesko, Steven Leonard Chapman, Solomon Moshkevich, Michael Burkes Brophy, Jonathan Sheena, James Healy, Herm Rosenman, Roy D Baynes, Gail Boxer Marcus and Rowan E Chapman. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings2/26/2026Today5/20/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 7 days, NTRA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:NTRA CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees6,140Year Founded2004Price Target and Rating Average Price Target for Natera$256.60 High Price Target$300.00 Low Price Target$172.00 Potential Upside/Downside+25.2%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$208.16 million Net Margins-9.05% Pretax Margin-11.44% Return on Equity-14.74% Return on Assets-10.27% Debt Debt-to-Equity RatioN/A Current Ratio2.96 Quick Ratio2.83 Sales & Book Value Annual Sales$2.31 billion Price / Sales12.73 Cash FlowN/A Price / Cash FlowN/A Book Value$12.39 per share Price / Book16.54Miscellaneous Outstanding Shares143,210,000Free Float135,152,000Market Cap$29.35 billion OptionableOptionable Beta1.57 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:NTRA) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Natera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
